Disease · MONDO_0005566
neonatal abstinence syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. neonatal abstinence syndrome. Diseases, record MONDO_0005566. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005566
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| CLONIDINE | CHEMBL134 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| METHADONE | CHEMBL651 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| MORPHINE | CHEMBL70 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PHENOBARBITAL | CHEMBL40 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CHLORPROMAZINE | CHEMBL71 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LAVENDER OIL | CHEMBL2108210 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| MORPHINE SULFATE | CHEMBL2103744 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALOXONE | CHEMBL80 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 5 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 2 | Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 1 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4985 | Drugs and targets |
Trials18
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00271219 | RCT Comparing Methadone and Buprenorphine in Pregnant Women | Phase 3 | 175 | 2015-08-05 | Opioid Related Disorders, Pregnancy, Opioid Dependence | BUPRENORPHINE, METHADONE | Its record names the disease | ClinicalTrials.gov |
| NCT01561079 | Fetal and Infant Effects of Maternal Buprenorphine Treatment | Phase 2/3 | 127 | 2017-08-28 | Neonatal Abstinence Syndrome | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT03396588 | Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain | Phase 3 | 120 | 2025-05-23 | Neonatal Abstinence Syndrome | CLONIDINE, MORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT01958476 | Improving Outcomes in Neonatal Abstinence Syndrome | Phase 3 | 117 | 2019-10-15 | Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal | METHADONE, MORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT01175668 | Clonidine for Neonatal Abstinence Syndrome Study | Not applicable | 68 | 2014-01-06 | Neonatal Abstinence Syndrome | CLONIDINE, PHENOBARBITAL | Its record names the disease | ClinicalTrials.gov |
| NCT03291847 | Maternal Buprenorphine-naloxone Treatment and the Infant | Phase 2 | 42 | 2023-12-20 | Maternal Opioid Use Disorder, Opioid Exposed Infant | BUPRENORPHINE, NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03097484 | The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels | Phase 3 | 38 | 2019-05-14 | Neonatal Abstinence Syndrome, Aromatherapy | LAVENDER OIL | Its record names the disease | ClinicalTrials.gov |
| NCT03670160 | Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome | Phase 2 | 25 | 2021-11-09 | Neonatal Abstinence Syndrome | CLONIDINE, PHENOBARBITAL | Its record names the disease | ClinicalTrials.gov |
| NCT01360450 | Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants | Phase 2/3 | 12 | 2017-09-13 | Neonatal Abstinence Syndrome | CLONIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT03134703 | Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome | Phase 2 | 11 | 2020-05-19 | Neonatal Abstinence Syndrome | METHADONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A Methadone vs B Buprenorphine: Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS) | 41 of 73 | 27 of 58 | 131 | NCT00271219 | Trial comparisons |
| Clonidine vs Morphine: deaths from any cause | 1 of 60 | 0 of 60 | 120 | NCT03396588 | Trial comparisons |
| Clonidine vs Morphine: serious adverse events | 9 of 60 | 15 of 60 | 120 | NCT03396588 | Trial comparisons |
| Methadone vs Neonatal Morphine Solution: Number of Infants Needing a Second NAS Medication | 10 of 58 | 17 of 58 | 116 | NCT01958476 | Trial comparisons |
| Methadone vs Neonatal Morphine Solution: Number of Infants Needing a Dose Increase | 22 of 58 | 28 of 58 | 116 | NCT01958476 | Trial comparisons |
| Methadone vs Neonatal Morphine Solution: deaths from any cause | 0 of 58 | 0 of 58 | 116 | NCT01958476 | Trial comparisons |
| Methadone vs Neonatal Morphine Solution: serious adverse events | 5 of 58 | 3 of 58 | 116 | NCT01958476 | Trial comparisons |
| NMS/Clonidine vs NMS/Phenobarbital: serious adverse events | 0 of 34 | 0 of 34 | 68 | NCT01175668 | Trial comparisons |
| Standard Therapy ALONE vs Standard Therapy Plus Aromatherapy: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT03097484 | Trial comparisons |
| Standard Therapy ALONE vs Standard Therapy Plus Aromatherapy: serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT03097484 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005566
GET https://conductscience.org/api/diseases/v1/MONDO_0005566/papers?page=2